157 related articles for article (PubMed ID: 16501420)
1. Results of severe sepsis treatment program using recombinant human activated protein C in Poland.
Kübler A; Mayzner-Zawadzka E; Durek G; Gaszyński W; Karpel E; Mikaszewska-Sokolewicz M; Majak P
Med Sci Monit; 2006 Mar; 12(3):CR107-12. PubMed ID: 16501420
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.
Kanji S; Perreault MM; Chant C; Williamson D; Burry L
Intensive Care Med; 2007 Mar; 33(3):517-23. PubMed ID: 17325837
[TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
[TBL] [Abstract][Full Text] [Related]
4. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
[TBL] [Abstract][Full Text] [Related]
5. The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series.
Berkman S; Weimert NA; Taber DJ; Baillie GM; Lin A; Baliga P; Chavin KD
Transpl Infect Dis; 2009 Jun; 11(3):269-76. PubMed ID: 19392728
[TBL] [Abstract][Full Text] [Related]
6. Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
Ely EW; Angus DC; Williams MD; Bates B; Qualy R; Bernard GR
Clin Infect Dis; 2003 Jul; 37(2):187-95. PubMed ID: 12856210
[TBL] [Abstract][Full Text] [Related]
7. Drotrecogin alfa (activated) for severe sepsis: could we consider a shorter treatment period in patients with a favorable course?
Ahishakiye D; Lorent S; De Backer D; Gottignies P; Vincent JL
J Crit Care; 2009 Dec; 24(4):590-4. PubMed ID: 19577419
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
[TBL] [Abstract][Full Text] [Related]
9. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
Frampton JE; Foster RH
Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
[TBL] [Abstract][Full Text] [Related]
10. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
[TBL] [Abstract][Full Text] [Related]
11. Bleeding complications with Drotrecogin alfa activated (Xigris): a retrospective review of 31 operative and 68 non-operative patients with severe sepsis.
Taylor BJ; Lee SJ; Waxman K
Am Surg; 2008 Oct; 74(10):898-901. PubMed ID: 18942609
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Kalil AC; LaRosa SP
Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
[TBL] [Abstract][Full Text] [Related]
13. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.
Laterre PF; Abraham E; Janes JM; Trzaskoma BL; Correll NL; Booth FV
Crit Care Med; 2007 Jun; 35(6):1457-63. PubMed ID: 17452935
[TBL] [Abstract][Full Text] [Related]
14. 90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.
Decruyenaere J; De Backer D; Spapen H; Laterre PF; Raemaekers J; Rogiers P; Trine H; Sartral M; Haentjens T; Wagner T
Acta Clin Belg; 2009; 64(1):16-22. PubMed ID: 19317237
[TBL] [Abstract][Full Text] [Related]
15. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
Bartelink AK
Ned Tijdschr Geneeskd; 2006 Feb; 150(7):352-4. PubMed ID: 16523795
[TBL] [Abstract][Full Text] [Related]
16. Risks and benefits of activated protein C treatment for severe sepsis.
Warren HS; Suffredini AF; Eichacker PQ; Munford RS
N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
[No Abstract] [Full Text] [Related]
17. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
[TBL] [Abstract][Full Text] [Related]
18. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
McCoy C
Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
[TBL] [Abstract][Full Text] [Related]
19. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
[TBL] [Abstract][Full Text] [Related]
20. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]